D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 78 Citations 32,105 280 World Ranking 10809 National Ranking 344

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Surgery

His primary scientific interests are in Internal medicine, Oncology, Surgery, Prostate cancer and Renal cell carcinoma. Kidney cancer and Nephrology are subfields of Internal medicine in which his conducts study. His Oncology study incorporates themes from Odds ratio, Cancer and Chemotherapy.

His Surgery research integrates issues from Urology, MEDLINE and Hazard ratio. His work carried out in the field of Prostate cancer brings together such families of science as Biopsy and Risk factor. The study incorporates disciplines such as Carcinoma and Nephrectomy in addition to Renal cell carcinoma.

His most cited work include:

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy (2853 citations)
  • EAU Guidelines on Renal Cell Carcinoma: 2014 Update (2354 citations)
  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy (1814 citations)

What are the main themes of his work throughout his whole career to date?

Peter F.A. Mulders mainly focuses on Internal medicine, Renal cell carcinoma, Oncology, Prostate cancer and Surgery. His biological study deals with issues like Placebo, which deal with fields such as Interim analysis. His Renal cell carcinoma research incorporates elements of Cancer research, Carcinoma and Nephrectomy.

Peter F.A. Mulders interconnects Chemotherapy, Castration resistant, Enzalutamide, Immunology and Immunotherapy in the investigation of issues within Oncology. His research integrates issues of Prostate and Urology in his study of Prostate cancer. His Surgery study often links to related topics such as Hazard ratio.

He most often published in these fields:

  • Internal medicine (42.01%)
  • Renal cell carcinoma (33.88%)
  • Oncology (31.98%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (42.01%)
  • Prostate cancer (27.10%)
  • Oncology (31.98%)

In recent papers he was focusing on the following fields of study:

Peter F.A. Mulders mostly deals with Internal medicine, Prostate cancer, Oncology, Renal cell carcinoma and Clear cell renal cell carcinoma. His study in Internal medicine is interdisciplinary in nature, drawing from both Major depressive disorder and Treatment-resistant depression. His Prostate cancer study combines topics in areas such as Biomarker, Prostate and Surgery.

His Oncology research includes themes of Clinical trial, Enzalutamide, Abiraterone acetate, Survival analysis and Cancer biomarkers. Peter F.A. Mulders has included themes like Radiology and Nephrectomy in his Renal cell carcinoma study. Peter F.A. Mulders focuses mostly in the field of Interim analysis, narrowing it down to matters related to Placebo and, in some cases, Hazard ratio.

Between 2016 and 2021, his most popular works were:

  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. (154 citations)
  • Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. (123 citations)
  • Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. (84 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Surgery

The scientist’s investigation covers issues in Internal medicine, Oncology, Prostate cancer, Renal cell carcinoma and Radiology. His study in Abiraterone acetate, Enzalutamide and Survival analysis are all subfields of Internal medicine. His biological study spans a wide range of topics, including Post-hoc analysis, Chemotherapy and Prednisone.

His studies in Prostate cancer integrate themes in fields like Framingham Risk Score and Surgery. His Surgery study integrates concerns from other disciplines, such as Biomarker, Prostate biopsy, Biopsy and PCA3. His Renal cell carcinoma research is multidisciplinary, incorporating perspectives in Kidney and Nephrectomy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin.
The New England Journal of Medicine (2012)

4023 Citations

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina.
The New England Journal of Medicine (2013)

2524 Citations

EAU Guidelines on Renal Cell Carcinoma: 2014 Update

Borje Ljungberg;Karim Bensalah;Steven Canfield;Saeed Dabestani.
European Urology (2010)

2354 Citations

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.

Thorgeir E Thorgeirsson;Frank Geller;Patrick Sulem;Thorunn Rafnar.
Nature (2008)

1502 Citations

GuidelinesEAU Guidelines on Renal Cell Carcinoma: The 2010 Update

Börje Ljungberg;Nigel C. Cowan;Damian C. Hanbury;Milan Hora.
European Urology (2010)

1495 Citations

Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo.
Journal of Clinical Oncology (2005)

816 Citations

SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE

Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck.
The Journal of Urology (2004)

782 Citations

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad.
Lancet Oncology (2015)

712 Citations

Renal cell carcinoma guideline.

Börje Ljungberg;Damian C. Hanbury;Marcus A. Kuczyk;Axel S. Merseburger.
European Urology (2007)

647 Citations

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Alexander Haese;Alexandre de la Taille;Hendrik van Poppel;Michael Marberger.
European Urology (2008)

514 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Peter F.A. Mulders

Francesco Montorsi

Francesco Montorsi

Vita-Salute San Raffaele University

Publications: 147

Shahrokh F. Shariat

Shahrokh F. Shariat

Medical University of Vienna

Publications: 141

Pierre I. Karakiewicz

Pierre I. Karakiewicz

University of Montreal

Publications: 123

Johann S. de Bono

Johann S. de Bono

Institute of Cancer Research

Publications: 120

Fred Saad

Fred Saad

University of Montreal

Publications: 102

Karim Fizazi

Karim Fizazi

Institut Gustave Roussy

Publications: 91

Alberto Briganti

Alberto Briganti

Vita-Salute San Raffaele University

Publications: 85

Vincenzo Ficarra

Vincenzo Ficarra

University of Udine

Publications: 81

Allan J. Pantuck

Allan J. Pantuck

University of California, Los Angeles

Publications: 79

Bernard Escudier

Bernard Escudier

Institut Gustave Roussy

Publications: 78

Christopher I. Amos

Christopher I. Amos

Baylor College of Medicine

Publications: 78

Arie S. Belldegrun

Arie S. Belldegrun

University of California, Los Angeles

Publications: 77

Kim N. Chi

Kim N. Chi

BC Cancer Agency

Publications: 71

Martin E. Gleave

Martin E. Gleave

University of British Columbia

Publications: 70

Cora N. Sternberg

Cora N. Sternberg

Cornell University

Publications: 69

Paul Russo

Paul Russo

Memorial Sloan Kettering Cancer Center

Publications: 68

Trending Scientists

Asit Dan

Asit Dan

IBM (United States)

R. L. Greene

R. L. Greene

University of Maryland, College Park

Kyong Yop Rhee

Kyong Yop Rhee

Kyung Hee University

Wayne D. Cook

Wayne D. Cook

Monash University

Roger Iván Rodríguez-Vivas

Roger Iván Rodríguez-Vivas

Autonomous University of Yucatán

Federico V. Pallardó

Federico V. Pallardó

University of Valencia

Sabrina Strano

Sabrina Strano

McMaster University

Rudolf Brázdil

Rudolf Brázdil

Czech Academy of Sciences

Cameron P. Wake

Cameron P. Wake

University of New Hampshire

Donald G. Stein

Donald G. Stein

Emory University

Daniel Buser

Daniel Buser

University of Bern

Takehiko Fujisawa

Takehiko Fujisawa

Chiba University

Ellen R. Wald

Ellen R. Wald

University of Wisconsin–Madison

Marco Colleoni

Marco Colleoni

European Institute of Oncology

Philip J. Rosenthal

Philip J. Rosenthal

University of California, San Francisco

Gloria Ladson-Billings

Gloria Ladson-Billings

University of Wisconsin–Madison

Something went wrong. Please try again later.